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Abstract: Small-diameter blood vessels (SDBVs) are still a challenging task to prepare due to the
occurrence of thrombosis formation, intimal hyperplasia, and aneurysmal dilation. Electrospinning
technique, as a promising tissue engineering approach, can fabricate polymer fibrous scaffolds that
satisfy requirements on the construction of extracellular matrix (ECM) of native blood vessel and
promote the adhesion, proliferation, and growth of cells. In this review, we summarize the polymers
that are deployed for the fabrication of SDBVs and classify them into three categories, synthetic
polymers, natural polymers, and hybrid polymers. Furthermore, the biomechanical properties and
the biological activities of the electrospun SBVs including anti-thrombogenic ability and cell response
are discussed. Polymer blends seem to be a strategic way to fabricate SDBVs because it combines
both suitable biomechanical properties coming from synthetic polymers and favorable sites to cell
attachment coming from natural polymers.
Keywords: SDBVs; thrombosis; electrospinning; fibrous scaffold; anti-thrombogenic agents
1. Introduction
Atherosclerosis is a cardiovascular disease that is caused by the decreased blood vessel fineness
due to the formation of plaques and blockage in the blood flow [1,2]. Angioplasty and surgical bypass
are common techniques to treat this disease. In the case of surgical bypass, vascular grafts function
to transfer the flow of blood instead of the damaged blood vessel. Vascular grafts are used for the
treatment of not only cardiovascular diseases, but also several other cases, such as dialysis, pediatric
heart operations, and mesenteric ischemia [3]. However, blood vessel replacement has limited clinical
success and it is rather expensive [4]. Although autologous vascular tissues have potential for blood
vessel replacement because of its biocompatibility and non-thrombogenic endothelium, harvesting
autologous vascular tissues may be difficult for some patients. Therefore, synthetic vascular grafts,
such as expanded polytetrafluoroethylene (ePTFE, i.e., Gortex) or poly (ethylene terephthalate) (PET,
i.e., Dacron), are developed. Since 1956, these materials have been clinically approved for large
diameter blood vessels and the occurrence of thrombosis is negligible owing to the high blood flow
and low resistance [5,6]. Although these materials are available and provided clinical efficiency, they
have low ratio of patency when employed for small diameter blood vessel (<6 mm). The reported
patency rates are 40% after six months and 25% after three years [7]. In addition, these materials are
non-degradable, which means that the patient is subject to cardiovascular surgery in the long term due
to the inability of tissue growth and remodeling. Therefore, some key criteria must be fulfilled when
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selecting a polymer to develop synthetic blood vessels, which are processability, mechanical property,
morphology and porosity, surface wetting property, degradability, and biocompatibility.
Tissue engineering is an emerging strategy to fabricate artificial vascular grafts (VGs). It aims
to the growth of extracellular matrix (ECM) through seeding cells on synthetic scaffolds. Various
strategies have been devoted to prepare scaffolds such as self-assembly, drawing, template synthesis,
phase separation, wet spinning, electrospinning [8,9], and their combination [10,11]. Scaffolds prepared
by fibrous materials are highly desirable, especially from nanofibers, because it has been shown that
the natural ECM of the tissues comprises three-dimensional (3D)-dimentioal fibrous structure with
fiber size in the range of 50–500 nm [12,13].
Most of nanofiber scaffolds are prepared by electrospinning. Electrospinning enables the
fabrication of fibrous scaffolds with fiber diameter ranging from nanometers to micrometers, which
have physical properties close to that of natural ECM [12,14]. For instance, the electrospun fibrous
scaffolds have high porosity, pore-interconnectivity, and large surface areas, providing suitable surface
sites to the cells to adhere, proliferate, and grow [14,15].
This review summarizes the progress in using electrospun nanofibers to develop small blood
vessels, i.e., those with a diameter below 6 mm. The biocompatibility studies both in vitro and in vivo
are described. State-of-the-art works on functionalization of nanofiber tissue scaffolds for the purpose
of promoting biocompatibility or decreasing blood clotting are discussed.
2. Native Blood Vessels
Natural blood vessels are classified into three types, namely, arteries, veins, and capillaries.
Arteries transfer the blood away from the heart and veins supply the blood back to the heart. Arteriole
is the name of small diameter artery and venule is the name of small diameter vein. Capillaries join
arteries and arterioles with vein and venules, and they also transfer gases and nutrients from blood to
tissues and vice versa.
The natural blood vessels have unique composition. The vessel walls comprise of three layers:
intima (inner layer), media (middle layer), and adventitia (outer layer), as illustrated in Figure 1 [16].
Intima layer is a monolayer of endothelial cells. Media layer consists of smooth muscle cells
(SMCs). Adventitia layer comprises collagenous extracellular matrix (ECM) that carries fibroblast and
perivascular nerve cells. Intima, media, and adventitia layers are separated from each other by lamina
layer containing elastin. Collagenous adventitia adds rigidity to the blood vessel walls, while lamina
provides them with elasticity [16]. Endothelial cell (EC) layer is located at the inner wall of blood
vessel, prohibiting the accumulation of blood and adjusting the number of smooth muscle cells (SMCs)
in the media layer. Blood vessels dilate and contract in response to a signal from ECs or cytokines [1].
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Figure 1. Schematic illustration of blood vessel structure (reprinted from Ref. [16]).
Table 1 lists the mechanical properties of some native blood vessels [17–21]. Confusingly, there is a
contradiction between the data outlined for the same tissues due to applications of different evaluation
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methods. For example, different values for the elastic modulus were reported for saphenous vein in
both the circumferential [17–19] and longitudinal directions [17,18].
Table 1. Mechanical properties of natural blood vessels.
Types Elastic Modulus(MPa)
Ultimate Stress
(MPa)
Strain at Failure
(%)
Burst Strength
(mmHg) Ref.
Saphenous vein (Circ.) 43 3 11 NA [17]
Saphenous vein (Long.) 130 13 17 NA [17]
Saphenous vein (Circ.) 4.2 1.8 242 1680–3900 [18]
Saphenous vein (Long.) 23.7 6.3 83 NA [18]
Saphenous vein (Circ.) 2.25 4 180 1250 [19]
Left internal mammary artery (Circ.) 8 4.1 134 2000 [18]
Left internal mammary artery (Long.) 16.8 4.3 59 NA [18]
Femoral artery (Circ.) 9–12 1–2 63–76 NA [20,21]
Circ.: circumferential; Long.: longitudinal; NA: not available.
Ideally, synthetic blood vessels should mimic the native blood vessels in both structure and functions.
They should be both biocompatible and bioactive, meanwhile, have acceptable mechanical properties.
3. Electrospinning Technique
Electrospinning shows great potential in the fabrication of fibrous scaffolds for developing blood
vessels. It can produce a seamless fibrous tube with fiber diameter controllable in either nanoscale or
microscale. In technology, electrospinning involves a physical process, in which a viscoelastic solution
is stretched into solution jet under a high electrostatic force and solidifies to form thin fibers. Figure 2a
schematically illustrates a basic setup for electrospinning, which contains a syringe with a syringe
pump, a needle nozzle, a collector, and a high voltage power supply. A polymer solution is normally
used as electrospinning material. When the solution is charged by high voltage, a Taylor cone is formed
at the tip of nozzle. A fine jet ejects from the tip of Taylor cone when the electric field overcomes the
surface tension. The charged jet then has an intensive interaction with the electric field formed between
the nozzle and the collector, making it undergo a whipping movement. Solvent evaporation from the
jet leads to solidification of the solution jet turning into fibers, which deposit onto the collector in the
form of randomly-oriented fibrous mats in most of the cases [13,22–24].
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Figure 2. Electrospinning setups: (a) grounded flat collector is used to collect fibers; (b) tubular rotating
mandrel is used to collect fibers to shape blood vessels.
The fiber morphology of electrospun fibers can be influenced by electrospinning parameters, e.g.,
solution viscosity, electrical co ductivity, poly er m lecular weight, applied voltage, flow rate of
polymer solution, spinning distance, and ambient condition, such as humidity and temperature [25,26].
Researches indicate that increasing polymer concentration, polymer molecular weight, or solution
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viscosity leads to increase in fiber diameter. Increasing the electrical conductivity of polymer solution
to certain extent decreases fiber diameter. There is a contradictory effect in case of applied voltage [25].
Some papers indicate that applied voltage has no influence on fiber diameter [27], while other papers
report that an increase or decrease in fiber diameter could both happen when increasing the applied
voltage during electrospinning [28]. The increase of solution flow rate increases the fiber diameter.
In addition, electrospinning technique can be used to directly fabricate tubular fibrous membrane,
useful as blood vessel scaffolds, as shown in Figure 2b. Several electrospinning setups have been
reported to fabricate blood vessels [29]. The tube diameter can be controlled by adjusting the diameter
of the collector.
4. Electrospun Fibrous Small-Diameter Blood Vessels
The fabrication of polymer fibrous scaffolds by electrospinning has been intensively investigated.
Various polymers have been used including synthetic polymer, natural polymer, and polymer blends.
Synthetic polymers exhibit better mechanical properties than natural polymers. Blending two synthetic
polymers or two natural polymers could result in enhanced mechanical properties.
Mechanical properties of artificial blood vessels play a major role when the vessels are attached to
the native vessels inside the body. If there is a match in the mechanical properties, the sheer stress, as
well as intimal hyperplasia can be avoided. Furthermore, the artificial blood vessels should be durable
enough to withstand the frequent blood circulation and the associated pressure.
4.1. Synthetic Polymer-Based Electrospun Scaffolds
Various attempts have been sought to fabricate artificial blood vessels using synthetic polymers
including polycaprolactone (PCL), poly(L-lactide-co-ε-caprolactone) (PLCL), poly-lactic acid (PLA),
polyurethane (PU), L-lactide-co-trimethylene carb, polypropylene (Moplen 462R PP), and polylactide
(PLA 4060D) [19,30–42].
4.1.1. Poly(ε-caprolactone)
Polycaprolactone (PCL) based blood vessels with inner diameter of 2 mm and wall thickness
of 650 ± 15 µm composed of a mixture of micro and nanofibers was fabricated. The fabricated
grafts demonstrated good mechanical properties. The longitudinal stress and strain to rupture were
4.1 ± 0.5 MPa and 1092 ± 28%, respectively. The burst pressure and suture retention strength were
measured at 3280 ± 280 mmHg and 936 ± 32 g, respectively. The average water leakage and average
blood leakage were evaluated to be 32.1 ± 1.3 mL min−1 cm−2 and 0.87 ± 0.08 mL min−1 cm−2 at
120 mmHg, respectively [30].
In another work, Poly(ε-caprolactone) micro and nanofibrous scaffolds with average fiber diameters
of 500–2500 nm and 1.9 µm were fabricated by electrospinning. The diameters of blood vessels were
2 mm and 4 mm, respectively. The fabricated blood vessels showed promising mechanical properties.
Both tensile stress and strain stress of the fabricated vascular grafts (2–7.4 MPa and 200–1200%) were
higher than that of native blood vessels (1.4 MPa and 100%). In fact, this higher mechanical property
is advantageous since the mechanical characteristics might experience a great decrease in clinical
conditions when the scaffold starts to degrade and the new natural tissues start to form [31].
Jin-Jia Hua et al. [32] reported that the higher the rotation speed during electrospinning of poly
([epsilon]-caprolactone) resulted in narrower fiber distribution and the higher the elastic modulus.
For instance, fibrous scaffolds fabricated at 250 rpm had elastic modulus up to 10 MPa while those
fabricated at 1500 rpm had elastic modulus up to 58 MPa.
Small diameter vascular graft was fabricated by electrospinning of poly(L-lactide-co-ε- caprolactone)
(PLCL). The diameter of the graft (2.3–2.5 mm) and the wall thickness of the graft (50–340 µm) increased
with the increase of electrospinning time from 10 min–100 min. The fiber diameter was in the range
between 700 nm and 800 nm. It was reported that [34] the thinner wall thickness of the synthetic
vascular conduit more complaint the synthetic vascular conduit. For example, the stiffness parameter
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(β) and diameter compliance (Cd) of the thinnest graft (Inner diameter = 2.3 ± 0.1 mm and wall
thickness = 49 ± 5 µm) is 6.8 ± 3.1 and 18.7 ± 11.2%/mmHg × 10−2, while it is 76.2 ± 18.0 and
2.0 ± 0.2%/mmHg × 10−2 for the thickest graft (Inner diameter = 2.5 ± 0.1 mm and wall thickness =
336 ± 21 µm) [33].
Bilayered tubular electrospun fibrous scaffold comprised pliable polymer Poly-ε-caprolactone
(PCL) at the inner layer and stiff polymer poly-lactic acid (PLA) at the outer layer was fabricated by
layer-by-layer using electrospinning technique, as shown in Figure 3a [34]. Figure 3b illustrates the
electrospun PCL scaffold consisting of microfibers and nanofibers with diameters of 1.5 µm to 6 µm
and 600 ± 400 nm, respectively, and interconnected pores with 15 µm average pore size. Figure 3c
shows the electrospun PLA scaffold consisting of nanofibers with diameters ranging from 800 nm
to 3000 nm and interconnected pores with 10 µm average pore size. The total porosity of PCL/PLA
scaffold is almost 79 ± 4%. The soft PCL layer mimics the intima layer of natural blood vessel, while
the tough PLA layer mimics the adventitia layer of natural blood vessel. The electrospun PCL/PLA
fibrous scaffold shows acceptable mechanical properties, with Young’s modulus of 30.9 ± 6.6 MPa
almost three times higher than that of PCL scaffold (10.7 ± 0.3 MPa) [34].
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Figure 3. SEM photographs of (a) synthetic poly(ε-caprolactone) (PCL)/Poly(L-lactic acid) (PLA) blood
vessel of 6 mm diameter, (b) the randomly oriented PCL fiber inner layer, (c) the aligned PLA fiber
outer layer (reprinted from Ref. [34]).
Combination of cell matrix engineering with electrospinning technology resulted in fabricating
enhanced poly(lactide-co-ε-caprolactone) (PLCL) nanofiber (1.05 ± 0.23 µm average fiber diameter)
based vascular grafts seeded with SMCs in terms of its mechanical characteristics [35]. The cell matrix
engineered PLCL vascular grafts demonstrated comparable mechanical properties to native rabbit
aorta, as well as high self-sealed property, due to the elasticity of PLCL. For instance, it gave tensile
strength values of 1.91 ± 0.56 MPa at a strain of 135% and 3.23 ± 0.57 MPa at a strain of 270% after
zero week and four weeks cell culture times, respectively, while the values that were obtained from
native rabbit aorta and GORE-TEX were 2.61 ± 0.4 MPa at a strain of 86.7% and 14.03 ± 0.72 MPa
at a strain 27.8%. Further, it gave elastic modulus values of 0.85 ± 0.14 MPa and 1.2 ± 0.3 MPa,
respectively, after zero week and four weeks cell culture times, while the obtained from native rabbit
aorta and GORE-TEX were 0.72 ± 0.1 MPa and 31.61 ± 4.76 MPa, respectively. The burst pressure
strength also showed improvement with the increase of c ll culture time; it was 604 ± 4 mmHg and
933 ± 22 mmHg, respectively, fter zero and fou weeks culture time, while it was 1323 ± 383 mmHg
and 1647 ± 201 mmHg for GORE-TEX and native rabbit aorta, respectively [35].
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Dynamic culture of poly(lactide-co-ε-caprolactone) synthetic blood vessel using SMCs in bioreactor
resulted in an enhancement of the burst strength (1298 ± 156 mmHg) greater than that measured at
the static culture (809 ± 44 mmHg) after two weeks [36].
4.1.2. Polyurethane (PU)
PU based vascular graft of 4 mm inner diameter, an average fiber diameter of 732.72 ± 52.22 nm
and a porosity of 50–60 showed tensile strength, rupture load, and ultimate elongation values of
5.85 ± 0.62 MPa, 16.5 ± 1.1 N, and 294.5 ± 19.4%, respectively [37]. Thermoplastic polyurethane was
modified by pentenoyl chloride of 20% concentration and then cross-linked during electrospinning
using UV irradiation. The fabricated blood vessel at diameter of 1.6 mm using the modified electrospun
polyurethane fibers showed burst pressure of 550 mmHg and compliance values of 12.1 ± 0.8 and
6.2 ± 0.3%/100 mmHg for uncross-linked and cross-linked fibers, respectively [38].
In another work, thermoplastic polyurethane (TPU) was modified by replacing the aromatic
diisocyanate MDI with aliphatic diisocyanate HMDI [39]. Further, the hydrolytic degradability was
increased by introducing cleavable chain extenders (CCEs), such as hydroxyethyl lactate (EGLA) and
bis (2-hydroxyethyl) terephthalate (BET), instead of the chain extender BDO. TPU containing EGLA
exhibited a degradability rate of two times faster than surgical poly (lactic acid) (PLA), while TPU
containing BET showed slower degradability rate than PLA. The modified TPU conduits showed
tensile stresses less than benchmark Pellethane due to the modification by aliphatic function group [39].
Polyurethane synthetic vascular graft of 4 mm in diameter and 48 mm in length was fabricated
by spin casting polyurethane layer first to pattern microgrooves on the lumen area and then
electrospinning polyurethane microfibers (average fiber diameter 1.20 ± 0.31 µm) on the outer layer,
as shown in Figure 4. The fabricated blood vessel exhibited acceptable mechanical properties with
Young’s modulus of 2.00 ± 0.40 MPa and strain stress of 300% [40].
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Figure 4. SEM image of polyurethane fibrous scaffold consists of micro-patterned internal layer and
electrospun microfiber external layer; the ridge width, channel width and channel depth were 3.6 ± 0.2,
3.9 ± 0.1 and 0.9 ± 0.03 µm, respectively (reprinted from Ref. [40]).
Blood vessels of diameter 4.7 mm and 1.3 mm at lengths of 30 mm and 10 mm, respectively, were
fabricated from TIPS/polyurethane ester urea (PEUU) fibrous scaffolds. The inner layer contained
porous scaffold of TIPS polymer casted using custom molds that had the same inner diameter of the
blood vessels; the outer layer had electrospun nanofibrous scaffold of PEUU, with average nanofiber
diameter of 743± 201 nm. The pore sizes of TIPS scaffold were 51± 3 µm and 123± 20 µm, respectively,
for 1.3 mm and 4.7 mm blood diameter vessels. The pore size of ES-PEUU nanofibers scaffold was
the same in both 1.3 mm and 4.7 m diameter blood vessels (5.1 ± 3.2 µm). The vessels showed
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comparable mechanical properties to the native blood vessels. For example, the elastic modulus was
1.4 ± 0.4 MPa, ultimate tensile stress was 8.3 ± 1.7 MPa, and the compliance and suture retention
forces were 4.6 ± 0.5 × 10−4 mmHg−1 and 3.4 ± 0.3 N, respectively [19].
4.1.3. Other Polymers
In addition to the aforementioned two synthetic polymers used as Scaffolds, many other
polymers have been reported showing excellent performances. For example, crosslinking L-lactide-co-
trimethylene carbonate fibrous scaffold by γ-radiation boosted the mechanical properties of the
synthetic fibrous scaffolds. The cross-linked scaffold had Young’s modulus matching the native human
artery (0.4 to 0.8 MPa) [41].
Melt electrospinning technique was employed for the manufacturing of synthetic blood vessel
that avoids the drawbacks of using solvents. It was found that the mass flow rate (MFR) had more
important influence on the structure of electrospun fibrous scaffold when compared to the other
fabrication parameters, such as voltage and distance between the spinneret and the collector. Tubular
vascular grafts were fabricated using polypropylene (Moplen 462R PP) and polylactide (PLA 4060D)
at the appropriate MFR (25 g/10 min and 2.16 kg at 230 ◦C), having average fiber diameters of 4.8 µm
and 3 µm, respectively, as shown in Figure 5. However, the random nature of the electrospun fibrous
scaffolds was obvious, which might affect the response of the cells either positively or negatively [42].
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Figure 5. Tubular blood vessels fabricated by melt electrospinning: (a,b) polypropylene (Moplen 462R
PP); (c,d) polylactide (PLA 4060D) (reprinted from Ref. [42]).
4.2. Natural Polymer-Based Electrospun Scaffolds
Natural polymers, such as silk, gelatin, and elastin, have also been employed to fabricate blood
vessels however demonstrating low mechanical properties, co pared to synthetic polymers [43–50].
Silk-based vascular graft of 5 mm intern l diameter and 0.15 mm wall thickness was fabricated.
The electrospun scaffold only demo strated elastic modulus, ultimate tensile stress and burst strength
of 2.45 ± 0.47 MPa, 2.42 ± 0.48 MPa, and 811 mmHg, respe tively [43].
Juan Z ou et al. [44] optimized conditions for the fabrication f silk fibroin based blood vessels
without the utilization of organic solvent that are 18 kV applied voltage, 18 cm collection distance, 37%
concentration, and 0.15 mL min−1 flow rate. Methanol treatment led to an increment of the tensile
strength value from 0.36 MPa to 3.57 MPa. Silk fibroin fibrous scaffold was fabricated by electrospinning,
followed by methanol treatment. The treated SF scaffold was more crystalline than untreated SF scaffold,
which was confirmed by DSC analysis and ATR-FTIR-ATR. The melting/decomposition temperature
and enthalpy measured by DSC analysis shifted to a higher value by increasing methanol treatment
time to 15 min, for untreated sample T (◦C) and ∆H were 279.70 and 130.13 Jg−1, for methanol treated
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sample T (◦C) and ∆H were 287.20 and 138.44 Jg−1. FTIR analysis indicated that the peak of β-sheet
structure is clearer after long methanol treatment (1699 cm−1) [44,45].
Gelatin is considered as collagen-derived product, which constitutes the major ratio of natural
blood vessel compositions. Gelatin nanofibrous tubular scaffold was electrospun with an internal
diameter of 5 mm and an average fiber diameter of 0.67 µm [46]. Crosslinking of the fabricated
scaffolds were achieved by immersing them in 15 mL 25% glutaraldehyde in a Petri dish for three days
at room temperature. After that, the cross-linked scaffolds were kept in a fume hood for 3 h to remove
glutaraldehyde. Crosslinking is a way for preventing the dissolution of fibrous scaffold when used as
vascular graft [47]. The cross-linked scaffolds showed reasonable mechanical properties relative to
natural collagen. For instance, the young’s modulus of the cross-linked scaffolds was about 33.8 MPa
in the axial direction whilst natural collagen has Young’s modulus of 5–10 MPa [48]. The cross-linked
scaffolds further showed an excellent tensile strength of 2.9 MPa in the axial direction when compared
to that of 60 KPa measured from human coronary artery. However, the strain to failure of these
scaffolds was 11.7% lower than that measured from arteries 35% [49].
The existence of elastin in natural arteries increases the strain to failure and reduces Young’s
modulus. Recombinant human tropoelastin (rTE) was utilized for the fabrication of electrospun blood
vessels and cross-linked by disuccinimidyl suberate (DSS) [50]. The electrospun rTE fibrous scaffold
showed encouraging mechanical characteristics ultimate tensile strength (UTS) of 0.36 ± 0.05 MPa,
elastic modulus of 0.91 ± 0.16 MPa, and burst pressure of 485 ± 25 mmHg [50].
4.3. Electrospun Scaffolds from Polymer Blends
Polymer blends have been employed as materials to fabricate blood vessels to achieve both
good mechanical properties and biocompatibility [51–62]. It was found that small diameter blood
vessel fabricated from poly(L-lactic acid)-co-poly(ε-caprolactone) P (LLACL 70:30) (3 mm internal
diameter) had mechanical properties closer to that of native abdominal aorta. For instance, P (LLACL)
fibrous scaffold demonstrated tensile strength of 3.9 ± 0.3 MPa in the circumferential direction, while
the native abdominal aorta showed tensile strength of 5.29 MPa in the same direction. Figure 6a,b
indicated that the fibrous scaffold almost retained its integrity up to 3 month after being immersed in
PBS solution at 37 ◦C [51].
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Figure 6. SEM images of in vitro degradation of P (LLACL) fibrous scaffold in PBS at 37 ◦C after (a)
0 time, (b) 3 months (reprinted from Ref. [51]).
Electrospun PU/PCL blend as used to construct small-diameter blood vessels (3 mm diameter,
0.5–2 µm fiber diameter, 0.5–150 µm pore size). The thus-constructed vessels demonstrated sufficient
mechanical properties (tensile strength: 18 MPa, Strain: 375% and pressure strength: 590–600 mmHg)
that met the requirement of vascular graft applications [52].
Poly(L-lactic acid) (PLA) and poly(ε-caprolactone) (PCL) (25:75) blend demonstrated better
biomechanical properties for cardiovascular graft applications (tensile strength 1.0 ± 0.3 MPa, tensile
strain 7.4 ± 2.3%, and suture retention strength 0.454 ± 0.047) than PLA/PCl (75:25) (tensile strength
2.6± 0.8 MPa, tensile strain 1.8± 1.2%, and suture retention strength 0.062± 0.025) [53]. Hybridization
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of silk fibroin with collagen can result in of small calibre blood vessels (6 mm diameter and 8 mm length)
with enhanced the mechanical properties. For instance, silk fibroin-collagen(SF-C) fibrous composite
showed burst pressure (894.00 ± 24.9 mmHg) and strain at failure (28.76 ± 1.39%), respectively, while
pure silk fibroin fibrous scaffolds (SF) only showed burst pressure (575.67 ± 17.47 mmHg) and strain
at failure (27.12 ± 2.63%), respectively [54].
Nanofibrous scaffolds comprised of gelatin/polycaprolactone (PCL) and collagen/poly(L-lactic
acid-co-ε-caprolactone) (PLCL) (average fiber diameter: 386.9 ± 102.5 nm and 301.8 ± 97.3 nm,
respectively) were tested in terms of their compatibility as vascular prostheses [55]. Both gelatin/PCL
and collagen/PLCL scaffolds demonstrated good wettability (contact angle = 0◦). More interestingly,
Young’s modulus of collagen/PLCL scaffold increased from 1.77 ± 0.09 MPa to 5.99 ± 0.80 MPa after
six weeks transplantation in nude mice as a result of vessel-like tissue formation, whilst Young’s
modulus of gelatin/PCL decreased from 1.49 ± 0.06 MPa to 0.75 ± 0.15 MPa after the same period of
transplantation [55].
Polydioxanone-elastin (50:50) blend demonstrated similar mechanical properties to that of native
femoral artery. PDO (100:0) showed an elastic modulus of 19.98 ± 0.74 MPa, ultimate stress of
5.57 ± 0.7 MPa, and strain at failure values of 206.33 ± 38.96%, while polydioxanone-elastin (50:50)
had the values of 9.64 ± 0.66 MPa, 3.25 ± 0.24 MPa, and 64.93 ± 3.97%, respectively, which were
approximate to values of Femoral artery (9 to 12 MPa, 1 to 2 MPa, and 63 to 76%) [56].
Collagen-elastin-poly(D,L-lactide-co-glycolide) (PLGA) (45%-15%-40%) blend was utilized in
fabricating small diameter blood vessel (4.75 mm inner diameter, 477 to 765 nm average fiber diameter,
and 0.5 mm wall thickness). The hybrid scaffold demonstrated tensile strength of 0.37 MPa and
young’s modulus of 0.85 MPa, respectively [57].
Polylactide-Silk Fibroin-Gelatin Composite based blood vessel (4.5 mm internal diameter, 0.5 mm
wall thickness, and 82% porosity) possessed breaking strength, strain, suture retention strength and
burst pressure strength values of 2.21 ± 0.18 MPa, 60.58 ± 1.23%, 4.58 ± 0.62 N, and 1596 ± 20 mmHg,
respectively [58,59].
4.4. Electrospun Layered Fibrous Scaffolds
Polycaprolactone, elastin and collagen have been used to fabricate tri-layered blood vessel resulting
in compliance ranging from 0.8 to 2.8%/100 mm Hg and young’s modulus ranging from 2.0 to 11.8 MPa.
The compliance and modulus measured for the tri-layered graft equal to that of native artery [60].
Collagen-chitosan-thermoplastic polyurethane (TPU) blends were used to fabricate vascular graft
blood vessel (3 mm in diameter). The fibrous scaffolds were electrospun in random and aligned
orientations consisting of fibers with diameters of 360 ± 220 nm and 256 ± 145 nm, respectively.
Both random fibrous scaffold and aligned fibrous scaffold showed average elongation at break
(9.87 ± 1.77% and 58.92 ± 15.46%, respectively) and average tensile strength (9.38 ± 1.04 MPa and
14.93 ± 0.59 MPa, respectively) [61].
Collagen and chitosan improved both the wettability and the biological surface properties
of poly(L-lactic acid-co-ε-caprolactone) P(LLA-CL). Collagen/chitosan/P(LLA-CL) (20:5:75) tubular
scaffold of 3 mm diameter, 1.1 ± 0.5 nm pore diameter, 409 ± 120 nm fiber diameter, and 0.33 ± 0.09
mm wall thickness showed ultimate stress (MPa), elongation at break (%), elastic modulus (MPa),
burst press (mmHg), compliance (mmHg), and contact angle of 16.9 ± 2.9 MPa, 112 ± 11% mmHg,
10.3 ± 1.1 MPa, >3365 ± 6 mmHg, 0.7 ± 0.4 mmHg and 110.5 ± 0.90, respectively [62].
Table 2 lists the polymers used for the fabrication of small diameter blood vessels and their relative
mechanical properties. It is quite clear that the mechanical properties of polymer blends are better than
both synthetic polymers and nature polymers.
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Table 2. Small diameter blood vessels prepared and their mechanical properties.
Polymers Solvents
Operating Conditions Mechanical Properties
Ref.
Polymer
Concentration
(w/v %)
Voltage
(kV)
Air Gap
(cm)
Flow Rate
(mL/h)
Spinning
Time (min)
Mandrel
Rotation Speed
(rpm)
Young’s
Modulus
(MPa)
Maximum
Stress
(MPa)
Maximum
Strain (%)
Burst
Strength
(mmHg)
Synthetic polymer-based scaffolds
PCL-PLA
CHCl3 12.5 13 20 0.6 180 3600 30.9 ± 6.6 4.3 ± 0.2 47.0 ± 6.3 [34]CHCl3/DMF 14 13 20 1.5 180 10800 10.7 ± 0.3 1.2 ± 0.1 260
PCL CHCl3/EtOH 15 20 12 6 4.8 600 [43]
PCL CHCl3/EtOH 5–15 15–25 12–24 4500 2–7.4 200–1200 [31]
TIPS-PEUU HFIP 8 10 1 250 1.4 ± 0.4 8.3 ± 1.7 [19]
PCL CHCl3/EtOH 15 20 12 6 4.1 ± 0.5 1092 ± 28 3280 ± 280 [30]
PLCL HFP 9 15 1 500 1.2 ± 0.3 3.23 ± 0.57 270 933 ± 22 [35]
PCL CHCl/MeOH
5 18 2 17.44 ± 0.91 13.35 ± 1.47 168.4 ± 8.76
[44]5 11 8 21.00 ± 1.39 8.72 ± 0.84 639.2 ± 24.15
Natural polymer-based scaffolds
Silk 10–11 0.9 3000 2.45 ± 0.47 2.42 ± 0.48 811 [45]
Gelatine TFE 10 30 1.5 50 2 33.8 2.9 11.7 [49]
(rTE) HFP 15 18.5 12.5 2 4400 0.91 ± 0.16 0.36 ± 0.05 485 ± 25 [53]
Hybrid polymer-based scaffolds
PDO-elastin (50:50) HFP 100 g/mL and200 mg/mL 22 12 4 and 8 500 9.64 ± 0.66 3.25 ± 0.24 64.93 ± 3.97 [59]
Collagen-elastin-PLGA HFP −20 22 10 3 500 0.85 0.37 [60]
PLLACL coated with collagen DCM/DMF 0 10 1 5 150 16.6 ± 4.4 3.9 ± 0.3 292 ± 87 [54]
PEUU-PMBU HFP 15 10 15 1 5 250 3 ± 1 342 ± 43 [63]
PLA-Silk Fibroin-Gelatin
formic solution 13 30 13 0.2 1000
2.21 ± 0.18 60.58 ± 1.23 1596 ± 20 [64]CHCl3/EtOH 5 25 15 0.1 2000
PCL-collagen HFP 1 20 10 3 1000 2.7 ± 1.2 4.0 ± 0.4 140 ± 13 4915 ± 155 [65]
PHBV-PCL CHCl3 1 20 15 0.5 3000 22 ± 7 1.4 ± 0.3 30 ± 20 [66]
Collagen-hitosan-P(LLA-CL) HFP/TFA 14 12–15 1 10.3 ± 1.1 16.9 ± 2.9 112 ± 11 >3365 ± 6 [67]
Lecithin-cholesterol-(Chol-PCL) CHCl3/DMF 18 15 3 35.92 ± 4.75 5.22 ± 0.50 107.15 ± 10.78 [68]
HFP: 1,1,1,3,3,3-hexafluro-2-propanol; TFE: 2,2,2-trifluoroethanol; DCM: dichloromethane; DMF: N,N-dimethylformamide; TFA: 2,2,2-trifluoroacetic acid.
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5. Biological Studies of Fibrous Small-Diameter Blood Vessels
Endothelialization of the synthetic blood vessel is a very important issue that affects some factors,
including anastomosis (attachment of the artificial blood vessels to the native blood vessels), intimal
hyperplasia resulting from the aggregation of particles inside the blood vessels, and thrombosis
formation resulting from blood clots.
Various polymers, whether synthetic, natural, or polymer blends, have been subject to in vitro
test and in vivo investigating. Natural polymers have better biocompatibility than synthetic polymers,
which can promote cell adhesion, proliferation, and growth. The strategy of blending polymers can
endow blood vessels with both high mechanical strength from synthetic polymers and the excellent
biocompatibility from natural polymers. Blending two synthetic polymers or two natural polymers
have also been tried, resulting in enhanced biological properties as well. In this section, several
strategies of in vitro tests and in vivo studies will be discussed.
5.1. In Vitro Studies
Research on the field of vascular graft fabrication points out that the cell-scaffold material
interaction is affected by how stiff the material is. ECs proliferation was found to be declined on
stiff gel-based scaffold [69]. Analogously, vascular smooth muscle cell proliferated 20 times higher
than that made of polydimethylsiloxane scaffold [70]. In contrary, the proliferation of human dermal
fibroblasts only had proportional relation with the stiffness of the matrix [71].
Gaudio et al. showed that Rat cerebral endothelial cells (RCECs) proliferated better on
electrospun poly(ε-caprolactone) (PCL) scaffolds and electrospun PCL/poly(3-hydroxybutyrate-co-3-
hydroxyvalerate) (PHBV) composite blends. However, apoptotic cells only appeared significantly
on PHBV fibrous scaffold due to the fact that PHBV presented stiffer characteristics [66]. A vascular
prosthetic of collagen/chitosan/P(LLA-CL) (20:5:75) promoted ECs cells interaction compared to
pure P(LLA-CL) [62]. Encapsulation of vascular endothelial growth factor (VEGF) in the fibrous
scaffold of chitosan hydrogel/poly(ethylene glycol)-b-poly(L-lactide-co-caprolactone) (PELCL) as inner
layer and platelet-derived growth factor-bb (PDGF) in the fibrous scaffold of emulsion poly(ethylene
glycol)-b-poly(L-lactide-co-glycolide) (PELGA)/PELCL as outer layer by coaxial electrospinning could
potentially control the proliferation of vascular endothelial cells (VECs) and Vascular smooth muscle
cells (VSMCs).VECs proliferated faster to cover the lumen of the graft (optical density = 1.4), while
VSMCs proliferated slower and adhered to the outer layer of the graft (optical density = 0.4) after three
days of culturing [72].
5.1.1. Endothelial Cells (ECs)
Small-diameter grafts (2.4 ± 0.1 mm inner diameter, 12 ± 13 µm wall thickness) made of poly(L-
lactide-co-ε-caprolactone) electrospun nanofibers were subject to endothelialization using human
umbilical vein endothelial cells (HUVECs); fiber diameters on the inner and outer surfaces were
799 ± 116 nm and 820 ± 121 nm, respectively. The researchers demonstrated that the gradual increase
of shear stress applied on the endothelialized grafts in a custom-designed mock circulatory instrument
from 3.2 N/m to 19.6 N/m could reduce the detachment of cells, increase the elongation of cells,
and align the cells and actin fibers with the direction of flow. This investigation provided reasonable
possibility for the retention enhancement of endothelial cells prior to implantation of the vascular
grafts [73].
The adhesion and proliferation of endothelial cells (HUVECs) on PU grafts shows no significant
difference that on PTFE grafts in the first three days. From the fourth day, cells had proliferated
extensively on PU grafts (absorbency 0.84) than on PU grants (absorbency 0.6) [37].
The patterned lumen of polyurethane vascular grafts enhanced the full endothelilization of
vascular grafts since the cells can migrate through these patterned channels shown in Figure 7 [40].
Aligned nanofibers enhanced BAEC cells response in comparison to random nanofibers when using
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synthetic blood vessel fabricated from absorbable poly-ε-caprolactone (PCL) with 4.5 inner diameter
and 400–500 nm average fiber diameter [67].Membranes 2018, 8, x FOR PEER REVIEW  12 of 26 
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Figure 7. Endothelial cells cultured inside the micro-patterned polyurethane-based synthetic blood
vessel after three days (reprinted from Ref. [40]).
PU/PCL blend scaffolds resulted in better hydrophilic properties (contact angle: 126◦), which
supported adhesion, proliferation and growth of cow pulmonary artery endothelial cells when cultured
for five days (optical density: 4% versus 1% for 1 day) [52].
Huma aortic endothelial cells are cultured on silk fibrous mats. They adhered and proliferated
well on the fibrous scaffold. However, human aortic endothelial cells did not migrate under the surface
of the fibrous scaffold due to the small size of the pores [43]. Recombinant human tropoelastin (rTE)
was used to fabricate blood vessels, which in turn, supported endothelial cell adhesion and growth [50].
Collagen coated P(LLACL) fibrous scaffold by air plasma treatment assisted adhesion, spread,
and proliferation of Human coronary artery endothelial cells (HCAECs) after 10 days of culture [51].
Researchers proved that double-layered fibrous scaffolds of poly(ε-caprolactone) (PCL) and
collagen blend with different fiber diameters (0.27 µm in inner layer and 4.45 µm in outer layer)
enabled confluent endothelization on the lumen of the inner layer when tubular vascular graft of
4.75 mm was fabricated [74–76].
Tubular sc ff ld was fabricated using recombinant spider silk rotein (pNSR32), polycaprolactone
(PCL), and gelatin (Gt) blend. The electrospun pNSR32/PCL/G (5:85:10) tubular scaffold showed
porosity, pore size, average fiber diameters and contact angle of 86.2 ± 2.9%, 2423 ± 979, 166 ± 85 nm
and 45.7 ± 13.70, respectively. The proliferation of Sprague Dawley Rat Aortic Endothelial Cells
(SDRAECs) on pNSR32/PCL/G scaffolds was higher than on pure PCL or even pNSR32/PCL after
seven days of culture, providing a higher proliferation index (PI) of 26.8% when compared to that
of PCL and pNSR32/PCL (17.8% and 21.5%, respectively) [77]. Similarly, pNSR32/polycaprolactone
(PCL)/chitosan (Cs) blend showed PI of 45.79 ± 0.79% and it could also help the seeded SDRAECs
cells to release higher conc tration of NO within s ven days of culture (40 µm/L for PCL/chitosan
blend versus 30 µm/L for pure PCL) [78].
Porcine iliac artery endothelial cells (PIECs) were cultured for seven days on both random and
aligned collagen-chitosan-thermoplastic polyurethane (TPU) fiber scaffolds, showing almost equal cell
viability on both scaffolds for PIECs (absorption index 1.6) [61].
5.1.2. Fib oblast Cells (FBCs)
Polyurethane grafts provided similar cytotoxicity to the commercial PTFE vascular grafts, and the
relative growth factor of mouse fibroblasts (L929) cells was almost 80% in both cases [35]. 3T3 mouse
fibroblasts cells adhered well to the surface of PCL/PLA scaffolds made of two layers after four weeks
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of cell culture shown in Figure 8. Human venous myofibroblasts (HVS) cells were concentrated in the
outer layer of PCL rather than in the inner layer of PLA, which was possibly due to the small pore size.
However, the cell content was almost 64% comparable to the native porcine pulmonary valve tissue,
indicating the progress of tissue growth [34].
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from Ref. [34]).
Human dermal fibroblasts could penetrate the surface of polydioxanone-elastin, although it was
stuck to the surface in case of pure PDO. It was clear that PDO boosted the mechanical properties of the
blend, elastin improved the elasticity and cellsinteractio because it can mimics the natural ECM [56].
3T3 mouse fibroblasts and human umbilical vein endothelial cells experienced good adhesion,
spread and proliferation when being seed d Polylactide-Silk Fibroin-Gelatin fibrous scaffold for
21 days [58,59]. NIH 3T2 fibroblast cells responded better on hybridized silk fibroin-collagen fibrous
scaffolds than pure silk fibroin fibrous scaffolds [54].
5.1.3. Smooth Muscle Cells (SMCs)
Poly(lactide-co-ε-caprolactone) (PLCL) nanofibers based vascular grafts seeded with SMCs
showed good biological properties [35], evidenced by the dramatically increased cell viability from
5 × 105 cells to 11 × 105 cells, respectively, with increasing cell culture time from zero week to seven
weeks. DNA content evaluation showed enhancement as a result of exte ding cell culture time from
zero w ek (1.4 ± 0.1 µg/µL) to four weeks (5.6 ± 0.3 µg/µL) [35].
Tubular fibrous scaffolds of poly(lactide-co-ε-caprolactone) 4 mm internal diameter experienced
better SMCs population during the dynamic culture in bioreactor than static culture. Both collagen
and DNA contents showed higher expressions in the case of dynamic culture than static culture
after two weeks (11.5 µg/mg and 35 µg/mg for collagen, respectively, and 5.7 ± 0.35 mg/µL and
7.5 ± 0.2 mg/µL for DNA, respectively) [36].
A combination of cell sheet technology with electrospinning resulted in harvesting robust
confluent cell sheet, which is difficult to obtain by cell sheet technolog alone [79]. Firstly,
micropatter ed polydimethylsiloxane (PDMS) was covered by N-isopr pylacrylamide (pNIPAm).
Secondly, an electrospun polycaprolactone (PCL) scaffold was mounted on the micropatterned PDMS
and then cultured by human aortic smooth muscles cells for four days. Eventually, the confluent
cell sheet was detached from the PMDS substrate upon cooling to room temperature and rolled over
mandrel of 3 mm diameter to form the synthetic blood vessel with contractile SMCs [80].
It has been noted that the expression of cultured SMCs on the electrospun poly(L-lactide) (PLLA)
fibrous scaffold covered with polydimethylsiloxane (PDMS) can be either pathogenic synthetic
phenotype or contractile phenotype depending on the alignment (random or aligned) of the PLLA
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scaffold. In the case of pathogenic synthetic phenotype, SMCs were able to swiftly proliferate and
migrate producing ECM components, like collagen and elastin. But, in the case of contractile phenotype,
SMCs were mature and it would not produce ECM, which was the case of healthy tunica media of
natural blood vessel [81,82].
Poly(ester amide) s (PEAs) was used as novel approach for fabricating synthetic blood vessels
and PCL was added up to 18–30% to enhance the electrospinnability. PEA-PCL fibrous scaffolds with
an average fiber diameter of 0.4 µm enhanced both the proliferation of human coronary artery smooth
muscle cells (HCASMCs) and the expression of elastin after seven days culture than PEA discs and
even PCL fibrous scaffold of the same fiber diameter [50]. For example, MTT assay revealed that the
absorbance of PEA-PCL fibers scaffold (780 nm) was higher than that measured for PCL fibers (450 nm)
and PEA films (600 nm). Further, the elastin expression of PEA-PCL fibrous scaffold was 230%, while
it was just 50% for PEA films and 100% for PCL fibers [83].
Ovine SMCs seeded on the blended scaffolds of Collagen/elastin/poly(D,L-lactide-co-glycolide)
(PLGA) (45%/15%/40%), providing mitochondrial 90% metabolic activity after seven days of
culture [57]. Human umbilical arterial smooth muscle cells seeded on gelatin/PCL and collagen/PLCL
scaffolds for 1 day and showed bipolar spindle shape indicating a contractile phenotype with an
optical densities of 0.2 and 0.3, respectively [55].
5.1.4. Mesenchymal Stem Cells (MSCs)
The higher porosity of polycaprolactone (PCL) scaffolds (30 µm and 5–6 µm average fiber
diameter) the faster the infiltration of cells and the formation of neoarteries. MSCs cells seeded on high
porous PCL resulted in expressing the macrophages in the immunomodulatory and tissue remodelling
(M2) phenotype while seeding on less porous PCL led to proinflammatory (M1) phenotype [44].
TIPS/polyurethane ester urea (PEUU) scaffold was tested using adult stem cells, demonstrating
cell density of 92 ± 1% [19]. Human mesenchymal stem cells adhered and proliferated well on
L-lactide-co-trimethylene carbonate fibrous scaffolds crosslinked by γ-radiation [41].
Electrospun poly (propylene carbonate) fibrous scaffold with 5 µm average fiber diameter was
used to fabricate vascular grafts (1.5–2 mm in diameter and 0.3–0.4 mm of wall thickness). Bone marrow
mesenchymal stem cells (MSCs) were cultured on the vascular grafts for 14 days and they showed
acceptable response in terms of adhesion, proliferation, and differentiation. The ability of eNOS
modified MSCs seeded blood vessels to produce NO (50 mg/mL) was closer to that detected from
fresh rat abdominal artery (68.4 mg/mL) with the same length shown in Figure 9 [84].
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Figure 9. Expression of transgene eNOS protein in both MSCs seeded blood vessel (a,b) and eNOS-
MSCs seeded blood vessel (c,d) (reprinted from Ref. [84]).
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5.2. In Vivo Studies
Blood vessel of 2 mm diameter fabricated from Poly(ε-caprolactone) (PCL) fibrous scaffold
of 1.90 µm average fiber diameter showed better patency rate when compared to expanded
polytetrafluoroethylene (ePTFE) grafts when being in vivo investigated in rat for 24 weeks. The growth
of endothelial cells and fibroblast cells with extra cellular matrix (ECM) was faster in case of PCL
and angiogenesis formation was also observed [63]. The histological analysis of blood vessel made of
PCL electrospun fibrous scaffold showed no thrombosis or aneurysm after the implantation of blood
vessels in an abdominal aortic rat after 12 weeks. Homogenous infiltration of cells along with the
degradation of the scaffold, ECM formation, and full endothelilization were also observed, as shown
in Figure 10 [31].
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Figure 10. Histological analysis for PCL electrospun blood vessel implanted in an abdominal aortic rat
for 12 weeks (a) 20 time, (b) 100 time, (c), and (d) 200 time magnification (reprinted from Ref. [31]).
Synthetic vascular grafts (1 mm diameter) that were made of poly(L-lactic acid) microfibers
modified by poly(ethylene glycol) and hirudin showed integration and remodelling with host
vasculature after being implanted in the carotid tery female sprague-dawley r ts. The elastic
modulus increased fro 3.5 MPa t 11.1 MP as a resu t of the implantation period increasing from one
month to six months, due to a significant remodeling of the grafts in vivo [85].
In vivo investigations of 1.3 mm diameter PMA modified conduits made of electrospun
biodegradable poly(ester urethane) urea (PEUU) modified with Nonthrombogenic 2-
methacryloyloxyethyl phosphorylcholine (MPC) copolymer in abdominal rat for 4, 8, 12, and
24 weeks resulted in patency rate of 92%, which was far higher than that observed for intact conduits
(40%). Neotissues c mprise of collagen and elastin as well as s ooth muscle cells (SMCs) and endothelial
cells (ECs) were observed after implant tion. Despite the fact that the constructed conduits demonstrated
higher compliance (4.5 ± 2.0 × 10−4 mmHg−1) than native rat aortas (14.2 ± 1.1 × 10−4 mmHg−1), they
reached the native values after four weeks of implantation. Nevertheless, they became stiffer in longer
period of implantation [86].
Thermoplastic polyurethane (TPU) conduits demonstrated good biological characteristics when
implanted in rat aorta for six months with no thrombin observed [43]. Polyurethane-based tubular
vascular grafts were fabricated with 1.5 mm internal diameter, 70 µm wall thickness and 0.88 µm fiber
diamete . The fabricated grafts how d 95% p tency rate fter implantation for seven days, four weeks,
three months, and six months in inbred Sprague-Dawley rats. CD34+, myofibroblasts and myocytes
cells showed good cell responses in terms of adhesion and proliferation. The ultimate circumferential
tensile stress of the grafts was also evaluated to be 26.4 MPa [79,87,88].
PCL-based grafts have not been extensively investigated in vivo for long term [45]. Therefore,
Sarra de Valence et al. showed that PCL grafts demonstrated good patency, endothelialization, and no
thrombosis was observed up to six months of implantation in abdominal aorta of rat. However, cells
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regression appeared after 12 and 18 months of implantation due to chondroid metaplasia formation
that was responsible for calcification of the grafts.
Small diameter blood vessels of 2.2 mm inner diameter were fabricated by electrospinning
polycaprolactone (PCL) comprising of fibrous scaffold with an average fiber diameter of 0.5 to 3 µm
and wall thickness of 500 µm. However, PCL surface is hydrophobic and bio-inert. The biomodification
of scaffold with arginine-glycine-aspartic acid (RGD)-containing molecule enhanced both patency rate
with no thrombosis observed after 4 weeks of implantation and SMCs and ECs infiltration. SMCs
covered almost 65.3 ± 7.6% of PCL-RGD surface area after four weeks of implantation, as shown in
Figure 11 [89].
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Figure 11. Investigation of explanted (a) PCL graft and (b) PCL-arginine-glycine-aspartic acid (RGD)
graft by stereomicroscope and (c,d) cross-section staining after four weeks of implantation. Acute
thrombosis was observed in the lumen of PCL (reprinted from Ref. [89]).
In vivo comparison study between polycaprolactone (PCL) and polytetrafluoroethylene (ePTFE)
was conducted fo 16.5 months. It was evid nt that PCL charact ristics match that of commercial ePTFE
in terms of patency rate (100% versus 67%), compliance (8.2 ± 1.0%/100 mmHg versus 5.7 ± 0.7%/
100 mmHg), endothelialization (100± 0.0% versus 99.6± 1.0%), cellular-in-growth (32.1± 9.2% versus
10.8 ± 4.0%), and calcification (7.0 ± 5.0% versus 15.8 ± 3.2%). Therefore, this study paves the way for
deeper analysis to commercially validate PCL based vascular grafts [90].
Fine mesh polyurethane grafts with low porosity (53%) increased cell adhesion and proliferation
at early stages in vivo than co rse me h polyure hane grafts with high porosity (80%) when implanted
in the r t model. However, cell populations were significantly impr ved by high porosity polyurethane
grafts. Fine and coarse mesh grafts both hold the same biomechanical properties before and after
transplantation, which were higher than native rat aorta. For instance, fine and coarse mesh grafts
demonstrated tensile strength of 20.2 ± 4.6 and 16.3 ± 0.9 MPa, respectively, which were higher than
that of native rat aorta 4.4 ± 0.9 MPa [91]. In vivo study of replacing inferior superficial epigastric
rabbit veins by P (LLACL) after s ven weeks implantation showed that the fabricated scaffold had
good patency, with no thrombosis observed [51].
Subcutainous implantation test of the PLA/SF-gelatin fibrous scaffold for three month in sprague-
dawley rat showed the absence of macrophages and lymphocytes, formation of vascular network,
and shape decrease of the scaffold. This all indicated that the scaffold has good biocompatibility and
biodegradability in vivo [58,59].
Hematoxylin and eosin (H & E) staining after subcutaneous implantation of gelatin/PCL and
collagen/PLCL scaffolds in nude mice for six weeks showed that gelatin/PCL formed heterogeneous
fibers with clear non-degraded scaffold, while collagen/PLCL led to the formation of vessel-like tissues
with homogenous surface and bands of collagen [55]. Table 3 lists polymers used for the fabrication of
small diameter blood vessels and their biostudies.
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Table 3. Polymers used for the fabrication of small diameter blood vessels and their biostudies.
Polymers
Cell Response
Ref.
In Vitro Study In Vivo Study
Synthetic Polymer-based Scaffolds
PCL-PLA
3T3 mouse fibroblasts cells covered the
surface of PCL/PAL fibrous scaffold after
4 weeks. Human venous myofibroblasts
(HVS) cells were concentrated in the outer
layer of PCL-PLA scaffold.
[34]
PCL
Implanted in a rat revealing that
endothelilization and extra cellular matrix
(ECM) formation of PCL was faster than
PTFE commercial grafts.
[49]
PCL
In vivo implantation in rat for 12 weeks
showed that the blood vessels were
completely endothelilized with
thrombosis formation.
[31]
TIPS-PEUU Cell culture resulted in density up to 92 ± 1%using Adult stem cells. [19]
PCL
Good patency rate, no thrombosis formation
and rapid endothelilization up to 6 months of
implantation in abdominal rat aorta.
However, calcium deposition appeared after
that at longer term of implantation.
[30]
PLCL
Smooth muscle cells (SMCs) were cultured
for up to 7 weeks. The viability of cells
increased by increasing cell culture time
(11 × 105 cells after 7 weeks).
[35]
PCL
Thicker fiber diameter based PCL graft
enhanced the formation of
immunomodulatory and tissue remodeling
(M2) phenotype when MSCs cells
were cultured.
[50]
Natural Polymer-based Scaffolds
Silk
Human aortic endothelial cells and coronary
artery smooth muscle cells experienced
good proliferation.
[51]
(rTE)
Tropoelastin based blood vessel showed good
endothelial cell response in terms of adhesion
and proliferation.
[49]
Hybrid Polymer-based Scaffolds
PDO-Elastin (50:50)
Human dermal fibroblasts cells cultured on
pure PDO and PDO-elastin blend for 7 days.
Hybrid scaffold of PDO-elastin showed better
cell response than pure PDO in terms of
adhesion, proliferation and migration.
[59]
Collagen-elastin-PLGA
Ovine SMCs cultured on
collagen/elastin/PLGA blend for 7 days
demonstrating good cell viability (90%).
[60]
PLLACL coated with
collagen
P LLA-CL-collagen vascular graft
demonstrated good cell response when
HCAECs are cultured.
P(LLA-CL)/collagen vascular graft
demonstrated good patency without
thrombosis formation when implanted in
rabbit veins.
[54]
PEUU-PMBU
Rat smooth muscle cells were cultured on
PEUU/PMBU fibrous scaffold for 1 day
resulting in diminishment of cell number
(70–76%) compared to the control (TCPS) and
pure PEUU.
Implanting the PEUU/ PMBU fibrous
scaffold in rat abdominal aorta showed
higher patency than PEUU.
[63]
PLA-silk Fibroin-Gelatin
3T3 mouse fibroblast cells cultured for
21 days on PLA/SF-gelatin showed good
proliferation.
Subcutaneous implantation test in
Sprague-dawley rat for 3 months resulted in
biocompatibility of the graft.
[64]
PCl-Collagen
Bovine endothelial cells (bECs) and smooth
muscle cells (SMCs) were cultured on
PCL-collagen fibrous scaffold demonstrating
confluent layer of ECs on the lumen of
the graft.
[65]
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Table 3. Cont.
Polymers
Cell Response
Ref.
In Vitro Study In Vivo Study
PHBV-PCL RCEC cells experienced apoptosis on PHBVbecause of its stiffness. [66]
Collagen-Chitosan-P
(LLA-CL)
ECs cells demonstrated good adhesion and
proliferation on collagen-chitosan-P(LLA-CL)
compared to pure P(LLA-CL).
[67]
Lecithin-cholesterol-PCL
MSC cells were cultured for 7 days on both
pure Chol-PCL and lecithin-Chol-PCL for
7 days. MSCs proliferated better on lecithin
doped Chol-PCL.
[68]
6. Functionalization of Fibrous Small-Diameter Blood Vessel Scaffolds
Pure fibrous scaffolds without any modifications may encounter thrombosis formation as a result
of blood clotting when transplanted in the animal model. Therefore, modification of the fibrous
scaffolds by antithrombogenic materials, such as hirudin, lecithin, antithrombogenic polymers, and
heparin, or drugs, such as dipyridamole (DPA) and aspirin, could terminate or significantly decrease
thrombi formation, enhance endothelialization, and further promote cell proliferation.
Functionalization of fibrous scaffolds could be done either by covalent attachment of the
antithrombogenic materials or by mixing antithrombogenic materials or drugs with the electrospinning
polymers during the electrospinning process. In this section, several ways for functionalizing fibrous
scaffolds are revised to point out the enhancement that occurred for the mechanical properties and
biological properties of the fibrous scaffolds after functionalization.
6.1. Anti-Thrombogenicity
Craig K. Hashi et al. showed that the modification of poly(L-lactic acid) microfibers with poly
(ethylene glycol) and hirudin could reduce platelet aggravation and appear no thrombin activity, due
to the existence of hirudin [85].
Lecithin/cholesterol-poly(ε-caprolactone) (Chol-PCL) electrospun fibrous scaffolds (average fiber
diameter 0.5 to 1 µm) showed better hemcompatibility and cytocompatibility than net Chol-PCL,
due to the zwitterionic property of lecithin. The hemolysis ratio (HR), which indicates the extent of
broken blood cells at the interface within the scaffold, was much lower in case of lecithin/Chol-PCL
(0.5%) than pure Chol-PCL (2.8%). Furthermore, the Lecithin/Chol-PCL conjugate demonstrated
biomechanical characteristics, including Tensile strength, Elongation at break (%), and Young’s modulus
of 5.22 ± 0.50 MPa, 107.15 ± 10.78%, and 35.92 ± 4.75 MPa, respectively. Bone-marrow mesenchymal
stem cells (MSCs) proliferated better on Lecithin/Chol-PCL with optical density of 0.9 nm higher than
that on pure Chol-PCL (0.65 nm) when being cultured for seven days [68].
Biodegradable poly (ester urethane) urea (PEUU) was used to fabricate conduits of small
diameter (1.3 mm internal diameter) followed by internally immobilization using nonthrombogenic
2-methacryloyloxyethyl phosphorylcholine (MPC) copolymer [86]. Firstly, the surface of PEUU
fibrous scaffold was aminated with amine groups using radio frequency glow discharge in ammonia
atmosphere. Following this, the amine sites reacted with the carboxyl groups of the PMA polymer
through condensation reaction to yield PMA functionalized PEUU fibrous scaffolds. The PMA
modified conduits showed reasonable biological activities when exposed to ovine blood since less
platelet adhesion observed when compared to untreated conduits [86].
Biodegradable poly(ester urethane) urea (PEUU) and non-thrombogenic bioinspired phospholipid
polymer (poly(2-methacryloyloxyethyl phosphorylcholine-co-methacryloyloxyethyl butylurethane)
(PMBU)) blend was used for the fabrication of small diameter blood vessels (1.3 mm internal
diameter, 300 µm wall thickness, and 500 nm average fiber diameter). The PEUU/15% PMBU blend
demonstrated Young’s modulus, strain, and compliance of 3 ± 1 MPa, 342 ± 43%, and 4.4 ± 1.1 ×
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10−4 mmHg−1, respectively, which were greater than that of pure PEUU (2 ± 1 MPa, 388 ± 58% and
2.9 ± 0.6 × 10−4 mmHg−1, respectively). The blended scaffold of PEUU/15% PMBU inhibited platelet
deposition as well as inhibited rat smooth muscle cells growth in vitro (RSMCs adhesion 70–76% after
one day). However, the vivo study of replacing rat abdominal aorta by PEUU/15% PMBU for three
months denoted that the fibrous scaffold had patency rate of 67%, which was higher than that of pure
PEUU (40%) [63].
Poly-ε-caprolactone (PCL) incorporated with peptide cysteine-alanine-glycine (CAG) was utilized
to fabricate electrospun small-caliber vascular grafts (SCVGs) of 0.7 mm diameter and 7 mm length.
The synthetic grafts were transplanted into the carotid arterial of sprague-Dawley rats for 6 weeks.
It was found that CAG containing grafts achieved higher endothelization ratio (97.4 ± 4.6%) than pure
PCL-based graft (76.7 ± 5.4%) after six weeks of implantation. On the other hand, α-smooth muscle
actin (ASMA) measured for a CAG/PCL graft (0.89 ± 0.06) was significantly less than that of pure
PCL graft (1.25 ± 0.22). Therefore, it is speculated that CAG/PCL grafts can enhance endothelilization
and inhibit intimal hyperplasia [92].
Combination of fused deposition (FDM) with electrospinning for fabricating vascular conduit
resulted in an enhancement of the overall biomechanical and biological characteristics [65].
Poly-L-lactide (PLLA)/heparin (Hep)/poly-ε-caprolactone (PCL) based blood vessels (5 mm diameter,
0.3 mm wall thickness, 6 cm length, and 450 ± 150 nm average fiber diameter) showed an ultimate
tensile strength of 1.58 ± 0.07 MPa, which was higher than that of electrospun poly-L-lactide
(PLLA)/heparin (0.72 ± 0.03 MPa) and human saphenous vein sample (SV) (1.15 ± 0.13 MPa), owing
to the existence of PCL coil layer deposited by FDM. Furthermore, live/dead assay (>90% viable cells)
and DNA content (4500 ng) showed high viability and proliferation of human adult bone marrow
mesenchymal stem cells (hMSCs) cultured on PLLA)/heparin/ PCL for 48 h [65].
Biomimetic small-diameter blood vessels (3 cm in length, 4 mm in inner diameter and 0.25 mm
in thickness) were fabricated by electrospinning gelatin-heparin (inner layer) and polyurethane (PU)
(outer layer). Both gelatin-heparin inner layer and PU outer layer demonstrated fiber diameter
between 108 nm and 174 nm, 587 nm to 1081 nm, respectively, average pore size 1.34 µm, and
1.60 µm, respectively. The thus-fabricated vessels acquired sufficient mechanical characteristics,
breaking strength (3.7 ± 0.13 MPa), and elongation at break (110 ± 8%). The release rate of heparin
was in the range of between 18.5% (1 day) and 33.0% (14 day). Consequently, it sounded that
the PU/Gelatin/Heparin based blood vessels held the structure of native vessels as well as it was
hemcompatible as a result of heparin release [93].
Heparin-poly(ε-caprolactone) conjugate was employed for the construction of small-diameter
blood vessel (Length = 4 cm, Diameter = 2 mm). PCL-heparin conjugate showed hydrophilicity (70◦)
higher than pure PCL (10◦). Since the surface of PCL-heparin conjugate was negatively charged, it
suppressed the adsorption of plasma protein like albumin and fibrinogen. Theoretically, the values of
albumin and fibrinogen should be 250 and 270 ng cm−2 respectively. Experimentally, the values were
500 ± 32 and 560 ± 40 ng cm−2 for pure PCL and 330 ± 21 and 340 ± 28 for PCL-heparin conjugate,
respectively. ECs cells achieved higher relative growth rate (RGR) in case of culturing on PCL-heparin
conjugate (160%) than pure PCL (100%). In vivo investigation was performed in dog’s femoral artery
using PCL-heparin graft for four weeks, resulting in potent and compatible graft. One can conclude
that the heparin containing graft is opportune to regenerative medicine since it is capable of supressing
thrombus formation [94]. Along the same lines, heparin was linked to the surface of poly(L-lactide)
(PLLA) by di-amino-poly (ethylene glycol) (PEG), which resulted in a greater patency rate (85.7%)
than untreated PLLA (42.9%), and promoted EC and SMC infiltration in the nanofibrous scaffolds [95].
Electrospun heparin/poly(L-lactide-co-ε-caprolactone) (P(LLA-CL) fibrous scaffold demonstrated
higher patency rate of 100% for two weeks implantation in canine model when compared to P(LLA-CL).
Furthermore, pre-endothelilized heparin/P(LLA-CL) fibrous scaffold got mechanical properties
(tension of 95776 ± 193 g/g and elongation of 8.8 ± 1.7 mm) higher than that of pure P(LLA-CL) and
even heparin/P(LLA-CL) [96].
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Bionic double layer small-diameter vascular graft (SDVG) of 2.5 mm diameter and 6 cm length
was constructed using heparin-conjugated polycaprolactone (hPCL) as inner layer (0.15 µm average
fiber diameter) and polyurethane (PU)-collagen blend as outer layer (0.2–1 µm average fiber diameter).
The constructed SDVG showed porosity of 45% and burst pressure of 300 kPa. In terms of its
biocompatibility, in vitro culturing of L929 fibroblast cells on the inner and outer scaffolds of SDVG
separately resulted in cell’s relative growth rates (RGR) of 103.5% and 98.0%, respectively. Moreover,
in vivo transplantation of SDVG in beagle dog model for almost eight weeks showed no aneurysmal
dilation, extravasation, and stenosis [97].
Tri-layered electrospun small-diameter vascular conduit (1.5 mm diameter and 300 µm wall
thickness), was constructed by co-electrospinning using poly(ε-caprolactone) (PCL) and natural
polymer chitosan (CS). The PCL/CS conduit was loaded by heparin, which attached to CS through ionic
bond. The internal layer of the conduit had higher concentration of CS (PCL/CS = 5/4 w/w), which in
turn absorbed higher concentration of heparin. Heparin conjugation led to remarkable anticoagulation
effect, which was proved by increasing activated partial thromboplastin time (APTT), thromboplastin
time (TT) and prothrombin time (PT) (180 s, 150 and 14 s, respectively), as well as decreasing platelets
adhesion (PCL/Cs 5/4 w/w: 100, PCL/Cs 5/4 w/w: 200). The PCL/Cs tube demonstrated acceptable
tensile strength and young’s modulus of 9 MPa and 7.8 MPa, respectively. In vitro test using EC and
SMC cells showed that heparin loaded PCL scaffolds promoted the proliferation of EC cells by the
secretion and stabilization of VEGF while inhibited moderately the proliferation of SMC cells by the
activation of intracellular pathways (O.D of ECs: 0.15 and O.D of SMCs: 0.1 after 1 day). This result
met the requirement of blood vessel regeneration because the high proliferation of SMC cells may lead
to intimal hyperplasia, especially at the initial stages. Both ex vivo shunt and in vivo implantation in
rat abdominal aorta for 1 month confirmed in vitro results demonstrating the absence of any thrombus
formation and blood leakage [98].
6.2. Drug Loadings
The incorporation of dipyridamole (DPA) into biodegradable elastic polyurethane urea (BPU)
fibrous scaffolds during electrospinning for the fabrication of small-diameter blood vessels (1.5 mm
diameter, 150 µm wall thickness, 520 ± 100 nm to 650 ± 160 nm average fiber diameter) led to
enhancement, both in the biomechanical properties and the biocompatibility. BPU + 10% DPA provided
tensile strength and strain value of 7.4 ± 0.1 MP (versus 3.4 ± 0.4 for pure BPU) and 107 ± 20%,
respectively. BPU + 10% DPA inhibited platelets adhesion (TAT concentration: 0.6 µg/mL against
1 µg/mL for pure BPU) and SMC cells proliferation, while it enhanced EC cells proliferation after
seven days culture [99].
7. Conclusions
Synthetic polymer, natural polymer, and hybrid polymer-based scaffolds have been intensely
used for the fabrication of small-diameter blood vessels. Electrospinning technique has advantages
over the varieties of other techniques that are used for the fabrication of fibrous scaffolds, because it
fabricates fibrous scaffolds with average fiber diameters in nano size from 50 to 500 nm. This fiber
sizes match that of natural ECM of native blood vessels. Nevertheless, electrospun nanofibers exhibit
some limitations, including the use of organic solvents, flat fibrous mat with limited control of pore
structure, and relatively low nanofiber mat strength, which need to be overcome for their intensive
application as tissue engineering scaffolds.
Various synthetic polymers have been utilized as blood vessels demonstrating good biomechanical
properties, including poly-ε-caprolactone (PCL), poly-lactic acid (PLA), polyurethane (PU), and poly
(lactide-co-ε-caprolactone) (PLCL). The mechanical properties as well as the cell response of fibrous
scaffolds of these polymers vary based on the elasticity of used polymer, the thickness of the fibers, and
the treatment employed before and after fabrication, including sterilization of α- or γ-radiations.
Bilayered scaffolds of PCL/PLA demonstrate enhanced mechanical properties in comparison to
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pure PCL (Young’s modulus: 30.9 ± 6.6 MPa versus 10.7 ± 0.3 MPa). The wall thickness of PLCL
fibrous scaffold affects its compliance. The thinner wall thickness is, the more compliant is the graft.
The incorporation of hirudin into PLA enhances the Young’s modulus from 3.5 to 11.1 MPa after six
months of implantation as well as inhibits platelet aggregations. The patency rate of poly(ester urethane)
urea (PEUU) experiences increment from 40% to 92% when being implanted in abdominal rate for
24 weeks due to the functionalization by nonthrombogenic 2-methacryloyloxyethyl phosphorylcholine
(MPC) copolymer. Increasing the porosity of polyurethane fibrous scaffold from 53% to 80% leads to an
increment of cell population upon implantation in rate model. Dynamic culture of SMCs in bioreactor
using PLCL fibrous scaffold show better collagen and DNA expressions compared to static culture for
two weeks. The incorporation of drug such as DPA into BPU fibrous scaffold enhances both the tensile
strength from 3.4 ± 0.4 MPa to 7.4 ± 0.1 MPa and ECs proliferation, while it inhibits SMCs proliferation.
Silk fibrous scaffold as natural polymer has contributed to the fabrication of SDBVs. Collagen
promoted the formation of vessel-like tissue better than gelatin when blended with PCL, which in turn
increases the young’s modulus from 1.77 ± 0.09 MPa to 5.99 ± 0.80 MPa upon implantation in nude
mice for six months. Gelatin fibrous scaffolds show enhanced mechanical properties as a result of
crosslinking by 15 mL 25% glutaraldehyde (for treated gelatin 33.8 MPa versus 5–10 MPa for untreated
gelatin). Nevertheless, the strain to failure is still low comparable to natural arteries (11.7% versus 35%
for artery). Elastin improves strain to failure although it decreases the modulus.
Hybridization of polymers provides an advanced strategy for the combination of good mechanical
properties and cell interaction with the scaffold materials. Several polymer blends whether synthetic
polymer blends or synthetic-natural polymer blends or natural polymer blends have all been employed
for the fabrication of SDBVs.
In addition to the previous attempts, the incorporation of antithrombogenic agents, such heparin
and lecithin, can lead to enhancement in the overall properties, along with the suppression of platelet
adhesion. PCl-heparin conjugate results in higher relative growth rate (RGR) (160%) than pure PCL
(100%) when cultured by ECs. Moreover, PLLA/heparin conjugate show higher patency rate (85.7%)
than that of pure PLLA (40%). Lecithin has/zwitterionic surface nature, which decreases hemolysis
ratio (HR) from 2.8% to 0.5% when conjugated with Chol-PCL scaffolds. Up to this end, a match
between synthetic blood vessels and native blood vessels in terms of composition and function may be
reachable by appropriate hybridization of polymers.
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